EYPT - EyePoint Pharmaceuticals Inc Stock Price, Fair Value and News

16.34USD-1.23 (-7.00%)Delayed as of 24 Apr 2024, 01:01 pm ET

Market Summary

USD16.34-1.23

Delayedas of 24 Apr 2024, 01:01 pm

-7.00%

EYPT Alerts

1 major insider buys recently.

EYPT Stock Price

View Fullscreen

EYPT RSI Chart

EYPT Valuation

Market Cap

875.5M

Price/Earnings (Trailing)

-12.37

Price/Sales (Trailing)

19.03

EV/EBITDA

-8.62

Price/Free Cashflow

-544.48

EYPT Price/Sales (Trailing)

EYPT Profitability

EBT Margin

-153.66%

Return on Equity

-26.58%

Return on Assets

-19.93%

Free Cashflow Yield

-0.18%

EYPT Fundamentals

EYPT Revenue

Revenue (TTM)

46.0M

Rev. Growth (Yr)

33.18%

Rev. Growth (Qtr)

-7.72%

EYPT Earnings

Earnings (TTM)

-70.8M

Earnings Growth (Yr)

67.55%

Earnings Growth (Qtr)

-11.79%

Breaking Down EYPT Revenue

52 Week Range

17.79

(Low)(High)

Last 7 days

-19.6%

Last 30 days

-21.1%

Last 90 days

-26.6%

Trailing 12 Months

126.3%

How does EYPT drawdown profile look like?

EYPT Financial Health

Current Ratio

5.45

EYPT Investor Care

Shares Dilution (1Y)

45.27%

Diluted EPS (TTM)

-1.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	39.8M	37.3M	42.5M	46.0M
2022	38.9M	41.5M	42.4M	41.4M
2021	34.3M	39.2M	32.5M	36.9M
2020	25.8M	22.8M	35.9M	34.4M
2019	5.7M	12.2M	14.2M	20.4M
2018	2.9M	3.0M	3.1M	4.6M
2017	6.1M	7.5M	7.6M	2.6M
2016	7.9M	1.6M	3.1M	4.6M
2015	26.4M	26.6M	20.3M	14.1M
2014	3.7M	3.5M	28.2M	28.1M
2013	2.4M	2.1M	2.2M	2.2M
2012	6.5M	3.5M	2.4M	2.4M
2011	9.5M	5.0M	6.1M	6.4M
2010	0	23.1M	18.5M	14.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of EyePoint Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	cormorant asset management, lp	bought	10,489,400	18.0304	581,765	-
Mar 30, 2024	paggiarino dario a.	sold (taxes)	-528,036	20.67	-25,546	chief medical officer
Mar 30, 2024	paggiarino dario a.	acquired	-	-	50,404	chief medical officer
Feb 27, 2024	duker jay s.	gifted	-	-	-2,500	president and ceo
Feb 27, 2024	duker jay s.	gifted	-	-	2,500	president and ceo
Feb 20, 2024	duker jay s.	gifted	-	-	20,000	president and ceo
Feb 20, 2024	duker jay s.	gifted	-	-	-20,000	president and ceo
Feb 13, 2024	lurker nancy	gifted	-	-	74,681	executive vice chair
Feb 13, 2024	lurker nancy	gifted	-	-	-74,681	executive vice chair
Feb 09, 2024	jones david scott	acquired	-	-	9,967	svp & chief commercial officer

Which funds bought or sold EYPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	211,272	322,916	-%
Apr 18, 2024	Park Place Capital Corp	new	-	475	475	-%
Apr 16, 2024	Cedar Mountain Advisors, LLC	unchanged	-	-2,440	20,670	-%
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	unchanged	-	-12,200	103,350	0.01%
Apr 15, 2024	Legato Capital Management LLC	added	20.87	111,232	1,482,740	0.18%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	reduced	-39.81	-1,152	1,344	-%
Apr 09, 2024	WOODSTOCK CORP	added	38.31	121,914	636,181	0.07%
Apr 05, 2024	CWM, LLC	new	-	1,000	1,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	9.3	-187	971	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	new	-	3,166,070	3,166,070	0.01%

Are Funds Buying or Selling EYPT?

Are funds buying EYPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EYPT

No. of Funds

EYPT Alerts

1 major insider buys recently.

Unveiling EyePoint Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	5.6%	2,522,704	SC 13G
Feb 14, 2024	ra capital management, l.p.	6.1%	3,095,136	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	9.99%	4,774,389	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	9.15%	4,466,420	SC 13G/A
Feb 06, 2024	franklin resources inc	9.5%	4,640,651	SC 13G/A
Dec 14, 2023	cormorant asset management, lp	12.36%	6,038,235	SC 13G/A
Dec 08, 2023	ew healthcare partners, l.p.	4.8%	2,247,432	SC 13D/A
Sep 11, 2023	franklin resources inc	11.8%	4,130,137	SC 13G/A
Aug 30, 2023	ew healthcare partners, l.p.	-	0	SC 13D/A
May 01, 2023	cormorant global healthcare master fund, lp	9.33%	3,200,000	SC 13G/A

Recent SEC filings of EyePoint Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	3	Insider Trading
Apr 22, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 08, 2024	10-K	Annual Report
Mar 07, 2024	8-K	Current Report
Mar 04, 2024	3	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	8-K	Current Report
Feb 28, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading

Peers (Alternatives to EyePoint Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

EyePoint Pharmaceuticals Inc News

Latest updates

EyePoint Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-7.7%	14,028,000	15,202,000	9,105,000	7,683,000	10,533,000	10,012,000	11,565,000	9,294,000	11,544,000	9,059,000	9,013,000	7,323,000	7,131,000	15,695,000	4,122,000	7,489,000	8,634,000	2,509,000	7,210,000	2,012,000	2,442,000
Operating Expenses	2.6%	30,382,000	29,600,000	31,866,000	29,237,000	54,270,000	28,410,000	30,781,000	27,578,000	29,593,500	24,372,000	19,992,000	18,258,000	19,868,000	17,652,000	15,274,000	18,933,000	17,618,500	16,569,000	17,375,000	16,663,000	13,447,000
S&GA Expenses	-61.4%	185,000	479,000	5,288,000	5,737,000	5,915,000	6,016,000	6,883,000	6,693,000	7,811,000	7,374,000	6,659,000	5,659,000	5,810,000	5,269,000	6,089,000	8,125,000	7,399,000	7,778,000	7,284,000	7,311,000	4,500,000
R&D Expenses	3.4%	17,951,000	17,363,000	15,730,000	13,618,000	15,543,000	11,162,000	12,992,000	9,945,000	8,918,000	8,498,000	5,605,000	5,479,000	5,205,000	4,090,000	3,276,000	4,853,000	4,131,500	3,484,000	3,955,000	3,797,000	4,179,000
EBITDA Margin	-25.8%	-1.50	-1.19	-1.34	-1.26	-1.20	-1.16	-1.17	-1.22	-1.28	-1.44	-1.19	-1.35	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	435,000	812,000	781,000	662,000	552,000	1,194,000	1,388,000	1,388,000	1,376,000	1,346,000	1,827,000	1,840,000	1,806,000	1,784,000	1,787,000	1,770,000	1,599,000	1,020,000	827,000
EBT Margin	-22.9%	-1.54	-1.25	-1.42	-1.34	-1.28	-1.25	-1.28	-1.37	-1.44	-1.63	-1.36	-1.55	-	-	-	-	-	-	-	-	-
Net Income	-11.8%	-14,099,000	-12,612,000	-22,920,000	-21,164,000	-43,452,000	-18,420,000	-19,406,000	-20,976,000	-19,432,000	-16,695,000	-10,010,000	-12,280,000	-15,469,000	-3,801,000	-12,950,000	-13,174,000	-10,410,000	-15,647,000	-11,498,000	-19,238,000	-11,594,000
Net Income Margin	34.7%	-1.54	-2.36	-2.84	-2.57	-2.47	-1.84	-1.85	-1.72	-1.58	-1.67	-1.06	-1.30	-	-	-	-	-	-	-	-	-
Free Cashflow	-41.8%	-23,992,000	-16,924,000	56,627,000	-17,319,000	-13,173,000	-14,334,000	-19,341,000	-20,307,000	-16,668,000	-7,918,000	-10,568,000	-15,099,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	121.9%	355	160	176	155	180	220	233	245	263	168	179	187	92.00	77.00	70.00	80.00	73.00	79.00	91.00	82.00	78.00
Current Assets	129.6%	345	150	167	146	173	192	206	220	238	142	152	159	63.00	48.00	40.00	50.00	42.00	47.00	59.00	48.00	48.00
Cash Equivalents	111.4%	281	133	140	106	96.00	75.00	82.00	102	179	120	128	139	45.00	29.00	23.00	26.00	22.00	32.00	44.00	44.00	45.00
Inventory	-14.7%	4.00	5.00	4.00	4.00	3.00	4.00	3.00	3.00	4.00	5.00	5.00	6.00	5.00	4.00	4.00	3.00	2.00	3.00	2.00	1.00	0.00
Net PPE	17.2%	5.00	4.00	3.00	3.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-12.4%	89.00	101	118	76.00	84.00	84.00	82.00	78.00	79.00	76.00	72.00	71.00	73.00	69.00	65.00	64.00	65.00	63.00	63.00	62.00	41.00
Current Liabilities	-1.0%	63.00	64.00	69.00	27.00	35.00	34.00	33.00	32.00	24.00	20.00	16.00	13.00	15.00	13.00	10.00	10.00	12.00	10.00	11.00	25.00	21.00
Short Term Borrowings	-	-	-	-	5.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	29.00	29.00	29.00	29.00	29.00	37.00	36.00	36.00	38.00	38.00	51.00	50.00	48.00	47.00	47.00	46.00	32.00	18.00
LT Debt, Non Current	-	-	-	-	29.00	29.00	29.00	29.00	29.00	37.00	36.00	36.00	38.00	38.00	51.00	50.00	48.00	47.00	47.00	46.00	32.00	18.00
Shareholder's Equity	354.3%	266	59.00	57.00	78.00	96.00	136	151	167	184	93.00	107	116	19.00	8.00	4.00	16.00	8.00	16.00	28.00	20.00	38.00
Retained Earnings	-1.9%	-742	-728	-715	-692	-671	-627	-609	-590	-569	-549	-532	-522	-510	-495	-491	-478	-465	-454	-439	-427	-408
Additional Paid-In Capital	28.2%	1,008	786	772	770	767	764	760	756	753	642	639	638	528	502	495	494	473	470	466	447	445
Shares Outstanding	38.9%	49.00	35.00	34.00	34.00	34.00	37.00	37.00	37.00	34.00	27.00	29.00	25.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	233	-	-	-	210	-	-	-	192	-	-	-	62.00	-	-	-	101	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-52.0%	-23,109	-15,204	57,023	-16,835	-12,588	-13,136	-19,123	-20,158	-16,668	-7,787	-10,543	-15,099	5,895	1,136	-5,121	-16,345	-11,486	-14,772	-17,107	-13,334	-10,820
Share Based Compensation	-1.1%	3,590	3,629	1,788	3,050	3,361	3,199	4,140	3,477	2,808	2,471	1,180	988	1,263	2,389	735	1,160	857	977	1,496	1,238	1,153
Cashflow From Investing	-2641.2%	-47,148	-1,720	13,467	32,086	32,917	6,272	-12.00	-56,442	-32,965	-131	-25.00	-	-192	-128	-26.00	-16.00	-6.00	-	-25.00	-182	-23.00
Cashflow From Financing	2008.5%	218,485	10,362	-36,658	-5,119	-58.00	92.00	-276	-448	108,516	-2.00	-381	108,769	10,480	4,904	1,662	20,446	1,945	2,371	17,914	11,634	341

EYPT Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 46,018	$ 41,404
Operating expenses:
Cost of sales, excluding amortization of acquired intangible assets	4,632	8,326
Research and development	64,662	49,642
Sales and marketing	11,689	25,507
General and administrative	40,102	34,817
Amortization of acquired intangible assets	0	2,050
Impairment of acquired intangible assets	0	20,699
Total operating expenses	121,085	141,041
Loss from operations	(75,067)	(99,637)
Other income (expense):
Interest and other income, net	6,949	2,131
Interest expense	(1,247)	(3,189)
Loss on extinguishment of debt	(1,347)	(1,559)
Total other income (expense), net	4,355	(2,617)
Net loss before income taxes	(70,712)	(102,254)
Provision for income taxes	(83)
Net loss	$ (70,795)	$ (102,254)
Net loss per share:
Net loss per share - basic	$ (1.82)	$ (2.74)
Net loss per share - diluted	$ (1.82)	$ (2.74)
Weighted average common shares outstanding:
Weighted average common shares outstanding - basic	38,904	37,317
Weighted average common shares outstanding - diluted	38,904	37,317
Net Income (Loss)	$ (70,795)	$ (102,254)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities, net of tax of $0 for periods presented	78	(55)
Comprehensive loss	(70,717)	(102,309)
Product [Member]
Revenues:
Total revenues	14,232	39,905
License and Collaboration Agreements [Member]
Revenues:
Total revenues	30,797	362
Royalty Income [Member]
Revenues:
Total revenues	$ 989	$ 1,137

EYPT Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 281,263	$ 95,633
Marketable securities	49,787	48,928
Accounts and other receivables, net	805	15,503
Prepaid expenses and other current assets	9,039	9,858
Inventory	3,906	2,886
Total current assets	344,800	172,808
Property and equipment, net	5,251	1,360
Operating lease right-of-use assets	4,983	6,038
Restricted cash	150	150
Total assets	355,184	180,356
Current liabilities:
Accounts payable	6,504	5,919
Accrued expenses	17,521	16,359
Deferred revenue	38,592	1,205
Short-term borrowings	0	10,475
Other current liabilities	646	579
Total current liabilities	63,263	34,537
Long-term debt		29,310
Deferred revenue - noncurrent	20,692	13,557
Operating lease liabilities - noncurrent	4,906	5,984
Other long-term liabilities		600
Total liabilities	88,861	83,988
Contingencies (Note 17)
Stockholders’ equity:
Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.001 par value, 300,000,000 shares authorized at December 31, 2023 and 2022, respectively; 49,043,074 and 34,082,934 shares issued and outstanding at December 31, 2023 and 2022, respectively	49	34
Additional paid-in capital	1,007,556	766,899
Accumulated deficit	(742,146)	(671,351)
Accumulated other comprehensive income	864	786
Total stockholders’ equity	266,323	96,368
Total liabilities and stockholders’ equity	$ 355,184	$ 180,356

About EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Jay S. Duker M.D.
WEBSITE	https://eyepointpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	144

EyePoint Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for EyePoint Pharmaceuticals Inc? What does EYPT stand for in stocks?

EYPT is the stock ticker symbol of EyePoint Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of EyePoint Pharmaceuticals Inc (EYPT)?

As of Tue Apr 23 2024, market cap of EyePoint Pharmaceuticals Inc is 875.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EYPT stock?

You can check EYPT's fair value in chart for subscribers.

What is the fair value of EYPT stock?

You can check EYPT's fair value in chart for subscribers. The fair value of EyePoint Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of EyePoint Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EYPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is EyePoint Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether EYPT is over valued or under valued. Whether EyePoint Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact EyePoint Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EYPT.

What is EyePoint Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, EYPT's PE ratio (Price to Earnings) is -12.37 and Price to Sales (PS) ratio is 19.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on EyePoint Pharmaceuticals Inc's stock?

In the past 10 years, EyePoint Pharmaceuticals Inc has provided -0.067 (multiply by 100 for percentage) rate of return.